{"id":3640,"date":"2022-07-01T09:05:15","date_gmt":"2022-07-01T07:05:15","guid":{"rendered":"https:\/\/cendoc.h12o.es\/blog\/?p=3640"},"modified":"2022-07-01T09:05:15","modified_gmt":"2022-07-01T07:05:15","slug":"tocilizumab-h12o-neumonia-y-covid-19","status":"publish","type":"post","link":"https:\/\/cendoc.h12o.es\/blog\/2022\/07\/01\/tocilizumab-h12o-neumonia-y-covid-19\/","title":{"rendered":"Tocilizumab, H12O, neumon\u00eda y COVID-19"},"content":{"rendered":"<p>Mario Fern\u00e1ndez Ruiz, de la Unidad de Infecciosas del Hospital 12 de Octubre, es el primer autor del siguiente art\u00edculo publicado en Medicina Cl\u00ednica<img loading=\"lazy\" decoding=\"async\" class=\" wp-image-3871 alignright\" src=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=244&amp;h=166\" alt=\"logo12\" width=\"244\" height=\"166\" data-attachment-id=\"3871\" data-permalink=\"https:\/\/coronavirusbiblioh12o.wordpress.com\/2020\/05\/06\/7-mas-del-h12o\/logo12\/\" data-orig-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg\" data-orig-size=\"275,183\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"logo12\" data-image-description=\"\" data-image-caption=\"\" data-medium-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" data-large-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" \/>: \u201cT<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0025775321003675?via%3Dihub\">ocilizumab en el tratamiento de la neumon\u00eda por SARS-CoV-2: an\u00e1lisis de una cohorte retrospectiva pareada<\/a>\u201d.<\/p>\n<p>Se trata de un estudio unic\u00e9ntrico de una cohorte retrospectiva de 47 pacientes con COVID-19 tratados con tocilizumab intravenoso (\u201cgrupo TCZ\u201d), emparejada por edad, comorbilidades mayores, evoluci\u00f3n de s\u00edntomas y cociente SpO<sub>2<\/sub>\/FiO<sub>2<\/sub> basal con otra cohorte de 47 pacientes que recibieron tratamiento est\u00e1ndar \u00fanicamente (\u201cgrupo SoC\u201d).<\/p>\n<p>No se observan diferencias significativas entre los grupos TCZ y SoC en la tasa de mejor\u00eda cl\u00ednica al 7\u00ba d\u00eda. Tampoco hubo diferencias al d\u00eda 14 en las tasas de mejor\u00eda cl\u00ednica, mortalidad o en el compuesto de ventilaci\u00f3n mec\u00e1nica invasiva y\/o muerte. Los pacientes en el grupo de TCZ presentaron una normalizaci\u00f3n m\u00e1s r\u00e1pida de la prote\u00edna C reactiva.<\/p>\n<p>Los autores concluyen que, respecto a una cohorte retrospectiva pareada, no se ha detectado un beneficio asociado al tratamiento con tocilizumab en pacientes con neumon\u00eda por COVID-19.<\/p>\n<p><em>Equipo Biblioteca H12O<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mario Fern\u00e1ndez Ruiz, de la Unidad de Infecciosas del Hospital 12 de Octubre, es el primer autor del siguiente art\u00edculo publicado en Medicina Cl\u00ednica: \u201cTocilizumab en el tratamiento de la neumon\u00eda por SARS-CoV-2: an\u00e1lisis de una cohorte retrospectiva pareada\u201d. Se trata de un estudio unic\u00e9ntrico de una cohorte retrospectiva de \u2026<\/p>\n<p class=\"continue-reading-button\"> <a class=\"continue-reading-link\" href=\"https:\/\/cendoc.h12o.es\/blog\/2022\/07\/01\/tocilizumab-h12o-neumonia-y-covid-19\/\">Continuar leyendo<i class=\"crycon-right-dir\"><\/i><\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2}},"categories":[4,64,46],"tags":[],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p3G9TJ-WI","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/3640"}],"collection":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/comments?post=3640"}],"version-history":[{"count":1,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/3640\/revisions"}],"predecessor-version":[{"id":3641,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/3640\/revisions\/3641"}],"wp:attachment":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/media?parent=3640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/categories?post=3640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/tags?post=3640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}